Back

Novel assay for quantifying the cholesterol crystal dissolution capacity of serum predicts outcomes in patients with severe aortic stenosis undergoing TAVR

27 August 2022 (08:15 - 09:00)
Organised by:
Congress Presentation Part of: Pathophysiology and disease progression in aortic stenosis Aortic Valve Stenosis ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Assistant Professor Baravan Al-Kassou

University hospital Bonn, Bonn (Germany)

7 More presentations in this session

Presentation thumbnail
Systemic proinflammatory-profibrotic response in aortic stenosis patients with diabetes and its relationship with myocardial remodeling and clinical outcome
Doctor H. Lee (Seoul, KR)
Abstract Slides
Presentation thumbnail
Association of anti-citrullinated peptide antibodies with the progression of aortic stenosis
Doctor A. Kim (Seoul, KR)
Abstract Slides
Presentation thumbnail
OAT3A1/NKD2 mediates increased calcification of aortic valvular interstitial cells under in vitro conditions of uremia
Doctor P. Duesing (Bonn, DE)
Abstract Slides
Presentation thumbnail
Characterisation of metabolic phenotype in aortic stenosis: insights from a multi-parametric cardiac magnetic resonance study
Doctor S. Monga (Oxford, GB)
Abstract Slides
Presentation thumbnail
Novel peripheral blood immune cell populations correlate with disease progression and reveal systemic interactions in severe aortic valve stenosis patients
Doctor N. Anousakis-Vlachochristou (Athens, GR)
Abstract Slides

Access the full session

Session thumbnail
Pathophysiology and disease progression in aortic stenosis

The Event

Event poster

ESC Congress 2022

27 August 2022 08:15 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources